Pfizer Says FY26 Adj. EPS Guidance Includes ~$0.10 Hit From $650M Innovent Licensing Charge
Share
Why It Matters
Pfizer is paying $650 million to license a medicine from another company. This cost will reduce their earnings by about 10 cents per share next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.